Search

Your search keyword '"Nolè, F"' showing total 459 results
Start Over Author "Nolè, F"
459 results on '"Nolè, F"'

1. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

Author

Choueiri, T.K., Penkov, K., Uemura, H., Campbell, M.T., Pal, S., Kollmannsberger, C., Lee, J.L., Venugopal, B., van den Eertwegh, A.J.M., Negrier, S., Gurney, H., Albiges, L., Berger, R., Haanen, J.B.A.G., Oyervides Juárez, V., Rini, B.I., Larkin, J., Nolè, F., Schmidinger, M., Atkins, M.B., Tomita, Y., Ellers-Lenz, B., Hoffman, J., Sandner, R., Wang, J., di Pietro, A., and Motzer, R.J.

Published
2024
Full Text
View/download PDF

2. Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

Author

Marvaso G, Volpe S, Pepa M, Zaffaroni M, Corrao G, Augugliaro M, Nolè F, De Cobelli O, and Jereczek-Fossa BA

Subjects
oligometastatic prostate cancer, metastasis-directed therapies, narrative review, imaging, biology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Giulia Marvaso,1,2,* Stefania Volpe,1,2,* Matteo Pepa,1,* Mattia Zaffaroni,1,* Giulia Corrao,1,2,* Matteo Augugliaro,1,* Franco Nolè,3,* Ottavio De Cobelli,2,4,* Barbara Alicja Jereczek-Fossa1,2,* 1Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy; 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 3Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO European Institute of Oncology IRCCS, Milan, Italy; 4Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy*These authors contributed equally to this workCorrespondence: Matteo PepaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, ItalyEmail matteo.pepa@ieo.itAbstract: After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new therapeutic options including metastases-directed therapies and new drugs have revolutionized the management of low-burden metastatic disease, also known as oligometastatic state. The purpose of this narrative review is to report the recent developments in the management of hormone-sensitive oligometastatic prostate cancer patients.Keywords: oligometastatic prostate cancer, metastasis-directed therapies, narrative review, imaging, biology

Published
2022

3. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Author

Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., and Sternberg, C.N.

Published
2021
Full Text
View/download PDF

5. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Author

Bossi, P., Miceli, R., Locati, L.D., Ferrari, D., Vecchio, S., Moretti, G., Denaro, N., Caponigro, F., Airoldi, M., Moro, C., Vaccher, E., Sponghini, A., Caldara, A., Rinaldi, G., Ferrau, F., Nolè, F., Lo Vullo, S., Tettamanzi, F., Hollander, L., and Licitra, L.

Published
2017
Full Text
View/download PDF

7. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Author

Ghi, M.G., Paccagnella, A., Ferrari, D., Foa, P., Alterio, D., Codecà, C., Nolè, F., Verri, E., Orecchia, R., Morelli, F., Parisi, S., Mastromauro, C., Mione, C.A., Rossetto, C., Polsinelli, M., Koussis, H., Loreggian, L., Bonetti, A., Campostrini, F., Azzarello, G., D’Ambrosio, C., Bertoni, F., Casanova, C., Emiliani, E., Guaraldi, M., Bunkheila, F., Bidoli, P., Niespolo, R.M., Gava, A., Massa, E., Frattegiani, A., Valduga, F., Pieri, G., Cipani, T., Da Corte, D., Chiappa, F., and Rulli, E.

Published
2017
Full Text
View/download PDF

9. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

Author

Gillessen, S., Choudhury, A., Saad, F., Gallardo, E., Soares, A., Loriot, Y., McDermott, R.S., Rodriguez-Vida, A., Isaacson, P., Nolè, F., Melo Cruz, F.J.S., Roumeguere, T., Daugaard, K.G., Yamamura, R., Lecouvet, F., Coens, C., Fournier, B., and Tombal, B.

Published
2024
Full Text
View/download PDF

25. Association of quantitative MRI-based radiomic features with prognostic factors and recurrence rate in oropharyngeal squamous cell carcinoma

Author

GIANNITTO, C., primary, MARVASO, G., additional, BOTTA, F., additional, RAIMONDI, S., additional, ALTERIO, D., additional, CIARDO, D., additional, VOLPE, S., additional, PIANO, F. DE, additional, ANCONA, E., additional, TAGLIABUE, M., additional, ORIGGI, D., additional, CHIOCCA, S., additional, MAFFINI, F. A., additional, ANSARIN, M., additional, BAGNARDI, V., additional, CATTANI, F., additional, NOLÈ, F., additional, PREDA, L., additional, ORECCHIA, R., additional, CASSANO, E., additional, CREMONESI, M., additional, STARZYŃSKA, A., additional, BELLOMI, M., additional, and JERECZEK-FOSSA, B. A., additional

Published
2021
Full Text
View/download PDF

26. PO-1218: Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?

Author

Marvaso, G., primary, Corrao, G., additional, Oneta, O., additional, Gugliandolo, S.G., additional, Pepa, M., additional, Cecconi, A., additional, Gandini, S., additional, Piperno, G., additional, Cossu Rocca, M., additional, Verri, E., additional, Aurilio, G., additional, Corso, F., additional, Cullurà, D., additional, Rondi, E., additional, Vigorito, S., additional, Nolè, F., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

27. 767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Banna, G.L., additional, Ermacora, P., additional, Morelli, F., additional, Nolè, F., additional, Marandino, L., additional, Panni, S., additional, Massari, F., additional, Hamzaj, A., additional, Milesi, L., additional, Santini, D., additional, De Tursi, M., additional, Scartozzi, M., additional, Astolfi, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

28. Oligometastatic prostate cancer: Multidisciplinary treatment vs. standard of care

Author

Mistretta, F.A., primary, Collà Ruvolo, C., additional, Conti, A., additional, Verri, E., additional, Marvaso, G., additional, Luzzago, S., additional, Vizziello, D., additional, Sabatini, I., additional, Bilato, M., additional, Zagami, P., additional, Catellani, M., additional, Di Trapani, E., additional, Cozzi, G., additional, Bianchi, R., additional, Ferro, M., additional, Cordima, G., additional, Brescia, A., additional, Musi, G., additional, Jereczek-Fossa, B.A., additional, Nolè, F., additional, and De Cobelli, O., additional

Published
2020
Full Text
View/download PDF

31. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

Author

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G, Cazzaniga M, contributor, Generali, D, Montemurro, F, Bordonaro, R, Mafodda, A, Romito, S, Michelotti, A, Piovano, P, Ionta, M, Bighin, C, Sartori, D, Frassoldati, A, Cazzaniga, M, Riccardi, F, Testore, F, Vici, P, Barone, C, Schirone, A, Piacentini, F, Nolè, F, Molino, A, Latini, L, Simoncini, E, Roila, F, Cognetti, F, Nuzzo, F, Foglietta, J, Minisini, A, Goffredo, F, Portera, G, Ascione, G, Mariani, G, Contributor, Generali, Daniele, Montemurro, F., Bordonaro, R., Mafodda, A., Romito, S., Michelotti, A., Piovano, P., Ionta, M. T., Bighin, C., Sartori, D., Frassoldati, A., Cazzaniga, M. E., Riccardi, F., Testore, F., Vici, P., Barone, C. A. ., Schirone, Alice, Piacentini, F., Nolè, F., Molino, A., Latini, L., Simoncini, E. L., Roila, F., Cognetti, Francesca, Nuzzo, Federica, Foglietta, J., Minisini, A. M., Goffredo, F., Portera, G., Ascione, G., and Mariani, G.

Subjects
0301 basic medicine, Oncology, Cancer Research, Advanced breast cancer, Everolimus, Hormone-receptor positive, Real life, Safety, medicine.medical_treatment, chemistry.chemical_compound, 0302 clinical medicine, Exemestane, Antineoplastic Combined Chemotherapy Protocols, Medicine, Neoplasm Metastasis, Aged, 80 and over, advanced breast cancer, everolimus, hormone-receptor positive, real life, safety, Middle Aged, Metastatic breast cancer, Everolimu, Italy, 030220 oncology & carcinogenesis, Female, medicine.drug, Hormone‐receptor positive, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Socio-culturale, Breast Neoplasms, Everolimus Plus Exemestane, Advanced Breast Cancer, BALLET Study, 03 medical and health sciences, Breast cancer, Internal medicine, Post-hoc analysis, Breast Cancer, Humans, Adverse effect, Aged, Chemotherapy, business.industry, medicine.disease, Androstadienes, Regimen, 030104 developmental biology, chemistry, business
Abstract

BACKGROUND: The BALLET study was an open-label, multicenter, expanded access study designed to allow treatment with everolimus plus exemestane in postmenopausal women with hormone receptor-positive metastatic breast cancer progressed following prior endocrine therapy. A post hoc analysis to evaluate if previous chemotherapy in the metastatic setting affects the safety profile of the combination regimen of everolimus and exemestane was conducted on the Italian subset, as it represented the major part of the patients enrolled (54%). PATIENTS AND METHODS: One thousand one hundred and fifty-one Italian patients were included in the present post hoc analysis, which focused on two sets of patients: patients who never received chemotherapy in the metastatic setting (36.1%) and patients who received at least one chemotherapy treatment in the metastatic setting (63.9%). RESULTS: One thousand one hundred and sixteen patients (97.0%) prematurely discontinued the study drug, and the main reasons reported were disease progression (39.1%), local reimbursement of everolimus (31.1%), and adverse events (AEs) (16.1%). The median duration of study treatment exposure was 139.5 days for exemestane and 135.0 days for everolimus. At least one AE was experienced by 92.5% of patients. The incidence of everolimus-related AEs was higher (83.9%) when compared with those that occurred with exemestane (29.1%), and the most commonly reported everolimus-related AE was stomatitis (51.3%). However, no significant difference in terms of safety related to the combination occurred between patients without and with chemotherapy in the metastatic setting. CONCLUSION: Real-life data of the Italian patients BALLET-related cohort were an adequate setting to state that previous chemotherapy did not affect the safety profile of the combination regimen of everolimus and exemestane. The Oncologist 2017;22:1-8Implications for Practice: With the advent of new targeted agents for advanced or metastatic breast cancer, multiple lines of therapy may be possible, and components of the combined regimens can overlap from one line to another. Thus, it is important to assess even the potential of cumulative and additive toxic effects among the drugs. Previous chemotherapy did not affect the safety profile of the combination regimen of everolimus and exemestane. The continuous monitoring of the safety signals of this drug combination from general clinical practice is important, in particular for stomatitis.

Published
2016

37. Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting

Author

Generali, D, Montemurro, F, Bordonaro, R, Mafodda, A, Romito, S, Michelotti, A, Piovano, P, Ionta, M, Bighin, C, Sartori, D, Frassoldati, A, Cazzaniga, M, Riccardi, F, Testore, F, Vici, P, Barone, C, Schirone, A, Piacentini, F, Nolè, F, Molino, A, Latini, L, Simoncini, E, Roila, F, Cognetti, F, Nuzzo, F, Foglietta, J, Minisini, A, Goffredo, F, Portera, G, Ascione, G, Mariani, G, Contributor, Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G, Cazzaniga M, contributor, Generali, D, Montemurro, F, Bordonaro, R, Mafodda, A, Romito, S, Michelotti, A, Piovano, P, Ionta, M, Bighin, C, Sartori, D, Frassoldati, A, Cazzaniga, M, Riccardi, F, Testore, F, Vici, P, Barone, C, Schirone, A, Piacentini, F, Nolè, F, Molino, A, Latini, L, Simoncini, E, Roila, F, Cognetti, F, Nuzzo, F, Foglietta, J, Minisini, A, Goffredo, F, Portera, G, Ascione, G, Mariani, G, Contributor, Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G, Cazzaniga M, and contributor

Abstract

Background. The BALLET study was an open-label, multicenter, expanded access study designed to allow treatment with everolimus plus exemestane in postmenopausal women with hormone receptor-positive metastatic breast cancer progressed following prior endocrine therapy. A post hoc analysis to evaluate if previous chemotherapy in the metastatic setting affects the safety profile of the combination regimen of everolimus and exemestane was conducted on the Italian subset, as it represented the major part of the patients enrolled (54%). Patients and Methods. One thousand one hundred and fiftyone Italian patients were included in the present post hoc analysis, which focused on two sets of patients: patients who never received chemotherapy in the metastatic setting (36.1%) and patients who received at least one chemotherapy treatment in the metastatic setting (63.9%). Results. One thousand one hundred and sixteen patients (97.0%) prematurely discontinued the study drug, and the main reasons reported were disease progression (39.1%), local reimbursement of everolimus (31.1%), and adverse events (AEs) (16.1%). The median duration of study treatment exposure was 139.5 days for exemestane and 135.0 days for everolimus. At least one AE was experienced by 92.5% of patients. The incidence of everolimus-related AEs was higher (83.9%) when compared with those that occurred with exemestane (29.1%), and the most commonly reported everolimus-related AE was stomatitis (51.3%). However, no significant difference in terms of safety related to the combination occurred between patients without and with chemotherapy in the metastatic setting. Conclusion. Real-life data of the Italian patients BALLET-related cohort were an adequate setting to state that previous chemotherapy did not affect the safety profile of the combination regimen of everolimus and exemestane.

Published
2017

38. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Author

Bossi, P, Cortinovis, D, Fatigoni, S, Cossu Rocca, M, Fabi, A, Seminara, P, Ripamonti, C, Alfieri, S, Granata, R, Bergamini, C, Agustoni, F, Bidoli, P, Nolè, F, Pessi, M, Macchi, F, Michellini, L, Montanaro, F, Roila, F, Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F, Bossi, P, Cortinovis, D, Fatigoni, S, Cossu Rocca, M, Fabi, A, Seminara, P, Ripamonti, C, Alfieri, S, Granata, R, Bergamini, C, Agustoni, F, Bidoli, P, Nolè, F, Pessi, M, Macchi, F, Michellini, L, Montanaro, F, Roila, F, Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, and Roila F

Abstract

Background: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. Patients and methods: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥ 2 chemotherapy cycles with high dose (>50mg/m2) cisplatin. Patients received ginger 160mg/day (with standardized dose of bioactive compounds) or placebo in addition to the standard antiemetic prophylaxis for CINV, starting from the day after cisplatin administration. CINV was assessed through daily visual-analogue scale and Functional Living Index Emesis questionnaires. The main objective was protection from delayed nausea; secondary end points included intercycle nausea and nausea anticipatory symptoms. Results: In total, 121 patients received ginger and 123 placebo. Lung (49%) and head and neck cancer (HNC; 35%) were the most represented tumors. No differences were reported in terms of safety profile or compliance. The incidence of delayed, intercycle and anticipatory nausea did not differ between the two arms in the first cycle and second cycle. A benefit of ginger over placebo in Functional Living Index Emesis nausea score differences (day 6-day 1) was identified for females (P=0.048) and HNC patients (P=0.038). Conclusions: In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV. The favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.

Published
2017

44. Very young women (

Author

Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., Luini, A., Veronesi, P., Intra, M., Orecchia, R., Catalano, G., Galimberti, V., Nolé, F., Martinelli, G., and Goldhirsch, A.

Published
2002
Full Text
View/download PDF

45. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development

Author

Cazzaniga, M, Camerini, A, Addeo, R, Nolè, F, Munzone, E, Collovà, E, Del Conte, A, Mencoboni, M, Papaldo, P, Pasini, F, Saracchini, S, Bocci, G, Cazzaniga M, Camerini A, Addeo R, Nolè F, Munzone E, Collovà E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, Bocci G, Cazzaniga, M, Camerini, A, Addeo, R, Nolè, F, Munzone, E, Collovà, E, Del Conte, A, Mencoboni, M, Papaldo, P, Pasini, F, Saracchini, S, Bocci, G, Cazzaniga M, Camerini A, Addeo R, Nolè F, Munzone E, Collovà E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, and Bocci G

Abstract

Metronomic chemotherapy (mCT), a frequent administration of low-dose chemotherapy, allows prolonged treatment duration and minimizes the toxicity of standard-dose chemotherapy. mCT has multiple actions against cancer cells including inhibition of angiogenesis and modulation of the immune system. A number of studies lend support to the clinical efficacy of mCT in advanced breast cancer and non-small-cell lung cancer. However, further evidence is necessary to describe the optimal use of mCT and to identify suitable patients. Oral vinorelbine has emerged as a promising metronomic treatment in patients with metastatic breast cancer and non-small-cell lung cancer and is the only orally available microtubule-targeting agent. This paper reviews current evidence on metronomic oral vinorelbine, discusses its management and defines a suitable patient profile on the basis of a workshop of Italian experts.

Published
2016

48. Association of quantitative MRI-based radiomic features with prognostic factors and recurrence rate in oropharyngeal squamous cell carcinoma.

Author

GIANNITTO, C., MARVASO, G., BOTTA, F., RAIMONDI, S., ALTERIO, D., CIARDO, D., VOLPE, S., DE PIANO, F., ANCONA, E., TAGLIABUE, M., ORIGGI, D., CHIOCCA, S., MAFFINI, F. A., ANSARIN, M., BAGNARDI, V., CATTANI, F., NOLÈ, F., PREDA, L., ORECCHIA, R., and CASSANO, E.

Subjects
RADIOMICS, SQUAMOUS cell carcinoma, PAPILLOMAVIRUSES, PHENOTYPES, MAGNETIC resonance imaging
Abstract

Radiomics focuses on extracting a large number of quantitative imaging features and testing both their correlation with clinical characteristics and their prognostic and predictive values. We propose a radiomic approach using magnetic resonance imaging (MRI) to decode the tumor phenotype and local recurrence in oropharyngeal squamous cell carcinoma (OPSCC). The contrast-enhanced T1-weighted sequences from baseline MRI examinations of OPSCC patients treated between 2008 and 2016 were retrospectively selected. Radiomic features were extracted using the IBEX software, and hiegrarchical clustering was applied to reduce features redundancy. The association of each radiomic feature with tumor grading and stage, HPV status, loco-regional recurrence within 2 years, considered as main endpoints, was assessed by univariate analysis and then corrected for multiple testing. Statistical analysis was performed with SAS/STAT® software. Thirty-two eligible cases were identified. For each patient, 1286 radiomic features were extracted, subsequently grouped into 16 clusters. Higher grading (G3 vs. G1/G2) was associated with lower values of GOH/65Percentile and GOH/85Percentile features (p=0.04 and 0.01, respectively). Positive HPV status was associated with higher values of GOH/10Percentile (p=0.03) and lower values of GOH/90Percentile (p=0.03). Loco-regional recurrence within 2 years was associated with higher values of GLCM3/4-7Correlation (p=0.04) and lower values of GLCM3/2-1InformationMeasureCorr1 (p=0.04). Results lost the statistical significance after correction for multiple testing. T stage was significantly correlated with 9 features, 4 of which (GLCM25/180-4InformationMeasureCorr2, Shape/MeanBreadth, GLCM25/90-1InverseDiffMomentNorm, and GLCM3/6-1InformationMeasureCorr1) retained statistical significance after False Discovery Rate correction. MRI-based radiomics is a feasible and promising approach for the prediction of tumor phenotype and local recurrence in OPSCC. Some radiomic features seem to be correlated with tumor characteristics and oncologic outcome however, larger collaborative studies are warranted in order to increase the statistical power and to obtain robust and validated results. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer

Author

Jereczek-Fossa, B. A., primary, Maucieri, A., additional, Marvaso, G., additional, Gandini, S., additional, Fodor, C., additional, Zerini, D., additional, Riva, G., additional, Alessandro, O., additional, Surgo, A., additional, Volpe, S., additional, Fanetti, G., additional, Arculeo, S., additional, Zerella, M. A., additional, Parisi, S., additional, Maisonneuve, P., additional, Vavassori, A., additional, Cattani, F., additional, Cambria, R., additional, Garibaldi, C., additional, Starzyńska, A., additional, Musi, G., additional, De Cobelli, O., additional, Ferro, M., additional, Nolè, F., additional, Ciardo, D., additional, and Orecchia, R., additional

Published
2018
Full Text
View/download PDF

50. Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy

Author

Bossi, P., primary, Depenni, R., additional, cossu rocca, M., additional, Ferrari, D., additional, Azzarello, G., additional, Alù, M., additional, Nolè, F., additional, Codecà, C., additional, Boscolo, G., additional, Piccininni, M., additional, Cavalieri, S., additional, Pugliese, G., additional, and Licitra, L.F., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results